@article{ref1,
title="Intra-trial mean 25(OH)D and PTH levels and risk of falling in older men and women in the Boston STOP IT trial",
journal="Journal of clinical endocrinology and metabolism",
year="2022",
author="Dawson-Hughes, Bess and Wang, Jifan and Barger, Kathryn and Bischoff-Ferrari, Heike A. and Sempos, Christopher T. and Durazo-Arvizu, Ramon A. and Ceglia, Lisa",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="CONTEXT: Supplementation with vitamin D has the potential to both reduce and increase risk of falling, and parathyroid hormone (PTH) may contribute to fall risk. <br><br>OBJECTIVE: To assess the associations of intra-trial mean circulating levels of 25-hydroxyvitamin D [25(OH)D] and PTH on incident falls in healthy older adults. <br><br>DESIGN: Observational within a clinical trial. SETTING: The Bone Metabolism Laboratory at the USDA Nutrition Center at Tufts University. PARTICIPANTS: 410 men and women age 65 years and older who participated in the 3-year Boston STOP IT trial to determine the effect of supplementation with 700 IU of vitamin D3 plus calcium on incident falls (secondary endpoint). Intra-trial exposures of 25(OH)D and PTH were calculated as the mean of biannual measures up to and including the first fall.Main outcome measures: incidence of first fall. <br><br>RESULTS: Intra-trial mean 25(OH)D was significantly associated with risk of falling in a U-shaped pattern; the range associated with minimal risk of falling was approximately 20-40 ng/ml. PTH was not significantly associated with risk of falling. <br><br>CONCLUSIONS: The findings highlight the importance of maintaining the circulating 25(OH)D level between 20 and 40 ng/ml, the range that is also recommended for bone health. At PTH levels within the normal range, there was no detectible independent association of PTH with fall risk.<p /> <p>Language: en</p>",
language="en",
issn="0021-972X",
doi="10.1210/clinem/dgac012",
url="http://dx.doi.org/10.1210/clinem/dgac012"
}